Interní Med. 2012; 14(3): 116-118

Options of treatment with insulin pumps

MUDr.Zdeněk Jankovec, Ph.D.
I. interní klinika, Fakultní nemocnice v Plzni

Treatment with an insulin pump has gradually become a routine part of care of patients with diabetes mellitus, particularly of those with

type 1 diabetes. Currently, approximately 5,500–6,000 patients, primarily centred in diabetes centres, are estimated to be treated with an

insulin pump in the Czech Republic. Due to frequent comorbidities, this treatment is not exclusively in the hands of diabetologists, but

increasingly involves the participation of physicians in other fields as well. The article aims at presenting a brief overview of the present

knowledge on treatment with an insulin pump and current indications and options of treatment. Insulin pumps have a firm place in the

care of diabetes patients; however, given the economic and personal demands of this treatment, it is necessary to carefully weigh all the

benefits and possible risks, including regular reappraisal of effectiveness of and indications for continuation of this treatment.

Keywords: insulin pump, CSII, diabetes mellitus, continuous glucose monitoring

Published: March 26, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jankovec Z. Options of treatment with insulin pumps. Interní Med. 2012;14(3):116-118.
Download citation

References

  1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986. Go to original source... Go to PubMed...
  2. Pickup J, Mattock M, Kerry A. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injection in patients with type 1 diabetes: metaanalysis of randomised controlled trials. BMJ 2002; 324: 1-6. Go to original source... Go to PubMed...
  3. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy. A meta-analysis. Diabetes Care 2003; 26: 1079-1087. Go to original source... Go to PubMed...
  4. Renner R, Pfutzner A, Trautmann M, et al. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Diabetes Care 1999; 22: 784-788. Go to original source... Go to PubMed...
  5. DeVries JH, Snoek FJ, Kostense PJ, et al. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 2002; 25: 2074-2080. Go to original source... Go to PubMed...
  6. Tsui E, Barnie A, Ross S, Parkes R, Zinman B. Intensive insulin therapy with insulin lispro: A randomized trial of continuous subcutaneuous insulin infusion versus multiple daily insulin injection. Diabetes Care 2001; 24: 1722-1727. Go to original source... Go to PubMed...
  7. Hirsch IB, Bode BW, Garg S, et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005; 28: 533-538. Go to original source... Go to PubMed...
  8. Pickup JC, Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008; 31 (Suppl 2): S140-145. Go to original source... Go to PubMed...
  9. Hanaire H, Lassmenn-Vague V, Jeandidier N, et al. Treatment of diabetes mellitus using an external insulin pump: the state of art. Diabetes & Metabolism 2008; 34: 401-423. Go to original source... Go to PubMed...
  10. Egger M, Davey Smith G, Stettler C, Diem P. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med 1997; 14: 919-928. Go to original source... Go to PubMed...
  11. Retnakaran R, Hochman J, DeVries JH, et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004; 27: 2590-2596. Go to original source... Go to PubMed...
  12. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with longterm continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 1996; 19: 324-327. Go to original source... Go to PubMed...
  13. Hoogma RP, Hammond PJ, Gomis R, et al. Comparison of the effect of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin infusion (IIR) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med 2006; 23: 141-147. Go to original source... Go to PubMed...
  14. Sherr J, Tamborlane WV. Past, present and future if insulin pump therapy: a better shot at diabetes control. Mt Sinai J Med 2008; 75 (4): 352-361. Go to original source... Go to PubMed...
  15. Li Y, Xu W, Liao Z, Yao B, et al. Induction of longterm glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of b-cell function. Diabetes Care 2004; 27: 2597-2602. Go to original source... Go to PubMed...
  16. Wainstein J, Metzger M, Wexler ID, et al. The use of continuous insulin delivery system in severely insulin-resistant patients. Diabetes Care 2001; 24: 1299. Go to original source... Go to PubMed...
  17. Wainstein J, Metzger M, Boaz M, et al. Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients. Diabetic Medicine 2005; 22: 1037-1046. Go to original source... Go to PubMed...
  18. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes. Diabetes Care 2003; 26: 2598-2603. Go to original source... Go to PubMed...
  19. Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005; 28: 1568-1573. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.